Female Sex Linked to Superior Outcomes in CD19-Directed CAR T-Cell Therapy for Large B-Cell Lymphoma
核心洞察
A real-world analysis of over 1,500 patients found significantly higher relapse risk and inferior survival in males versus females treated with CD19-directed CAR T-cell therapy (搜索) for large B-cell lymphoma (搜索).
The progression-free survival and overall survival differences were significant and more pronounced among patients younger than 50 years.
Researchers attribute the disparity to sex hormone effects on immune responses, including estradiol-driven upregulation of CD4+ T-cells and immunosuppressive properties of androgens.
A first-of-its-kind real-world analysis of more than 1,500 patients treated with CD19-directed CAR T-cell therapy (搜索) for aggressive large B-cell lymphoma (搜索) (LBCL) has identified female sex as a significant driver of superior outcomes, according to findings shared by Muhammad Bilal Abid, Medical Director of the Blood and Marrow Transplantation and Cellular Therapy Program at Texas Tech University Health Sciences Center.
The study, titled "Female sex is associated with superior outcomes in patients treated with CD19-directed CAR T-cell therapy (搜索) for large B-cell lymphoma (搜索)," found a significantly higher relapse risk and inferior survival in males compared to females. The progression-free survival (PFS) and overall survival (OS) differences were significant and were more pronounced among patients younger than 50 years.
The authors, including John Behman, Nausheen Ahmed, Shahrukh Hashmi, Mahmoud Aljurf, Farrukh Awan, Praveen Ramakishnan, Mumtaz Yaseen, Mohamed A. Kharfan-Dabaja, Sairah Ahmed, and Muhammad Bilal Abid, describe the analysis as the first real-world examination of sex-based differences in this treatment context.
Biological Rationale for Sex-Based Differences
The observed disparities are grounded in established immunobiology. The researchers note that sex hormones influence immune responses, with females mounting more vigorous antibody- and cell-mediated immune responses compared to males following infections or vaccinations.
Specifically, estradiol is associated with upregulation of CD4+ T-cells and dendritic cells, survival of autoreactive B-cells, and tumor necrosis factor (TNF) production. In contrast, androgens possess immunosuppressive properties. The authors also point out that gender-based differences with conventional immunotherapy in solid tumors have previously been demonstrated.
Implications for Future Research
The findings carry direct implications for the design and interpretation of CAR T-cell therapy studies. The authors recommend that broad-based sex differences should be incorporated into CAR-T studies, and they raise the question of whether optimized hormone replacement therapy (HRT) could be harnessed to enhance responses and improve survival in patients receiving T-cell therapies.
The work sets the premise for prospective validation of sex-specific differences in CAR T-cell therapy outcomes. As a next step, the investigators report they are in the process of writing a grant to identify immune correlates and gain mechanistic insights into the hormonal impact on cell therapy outcomes.
The study is part of a broader research effort led by Abid and collaborators across multiple academic centers, the CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, BMTCTN (Blood and Marrow Transplant Clinical Trials Network), SWOG Cancer Research Network, and the US Myeloma Immunotherapy Consortium. This program has examined drivers of cellular therapy outcomes, including the impact of lymphodepletion chemotherapy, infections, immune reconstitution, hormonal status, and gender, uncovering newer associations that warrant prospective evaluation.